What are the imaging findings in aHUS?

May 3, 2019 ... In an open-label study involving 14 patients with highly clinically active, AQP4-IgG–positive disease, the use of eculizumab reduced the frequency of relapse. May 7, 2019 ... Treatment with eculizumab (Soliris, Alexion Pharmaceuticals) significantly reduces the risk for relapse among patients with AQP4-IgG ... See full prescribing information for. SOLIRIS. SOLIRIS® (eculizumab) injection, for intravenous use. Initial U.S. Approval: 2007. WARNING: SERIOUS MENINGOCOCCAL ... Jan 23, 2024 ... This trial was a phase 3, patient-blinded, randomized control study assessing the impact of eculizumab on the course of acute renal failure in patients with ... Access to Eculizumab for patients with aHUS. NHS England published NICE guidance for the use of Eculizumab for treating in aHUS in January 2015. Sep 13, 2024 ... Soliris (eculizumab) is a prescription drug that's used to treat certain rare autoimmune conditions. Soliris is given as an intravenous (IV) infusion by a ... Alexion Pharmaceuticals, Inc. SOLIRIS. Prescribing information. Alexion Pharmaceuticals, Inc. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin ... Soliris 300 mg concentrate for solution for infusion. Active Ingredient: eculizumab. Company: Alexion Pharma UK Ltd. See contact details. A specific anti-complement treatment (eculizumab; its brand name is Soliris) ... If eculizumab is started, how long does it need to be continued? When a ... What side effects may I notice from receiving this medication? · Back pain · Cough · Diarrhea · Dizziness · Headache · Joint pain · Muscle pain · Nausea ...